Advertisement
News
Subscribe to MDT Magazine News

Novartis Gains FDA Approval for Afinitor® as First New Treatment in Nearly Three Decades for Patients with Advanced Pancreatic NET

May 5, 2011 5:35 pm | by Bio-Medicine.Org | Comments

EAST HANOVER, N.J., May 5, 2011 /- Novartis Pharmaceuticals Corporation ("Novartis") announced today that the US Food and Drug Administration (FDA) approved Afinitor® (everolimus) tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients...

TOPICS:

PerkinElmer 1Q profit slips 4 percent(2)

May 5, 2011 4:46 pm | by The Associated Press | Comments

Health and industrial sciences company PerkinElmer Inc. said Thursday its profit fell 4 percent in the first quarter on charges related to businesses it has sold.PerkinElmer said its profit slipped to $23.5 million, or 20 cents per share, from $24.4 million, or 21 cents per share, a year ago....

Quidel to Present at Bank of America Merrill Lynch Health Care Conference

May 5, 2011 4:45 pm | by The Associated Press | Comments

Quidel Corporation (NASDAQ: QDEL), a leading provider of rapid diagnostic testing solutions and cellular-based virology assays, announced today that it will present at the Bank of America Merrill Lynch Health Care Conference to be held at the Encore at Wynn hotel in Las Vegas, Nevada on...

Advertisement

Surgery reduces risk of mortality due to prostate cancer even for low-risk groups

May 5, 2011 2:37 pm | by EurekAlert | Comments

(Uppsala University) A Swedish research team partly consisting of researchers from Uppsala University followed a group of prostate cancer patients in the Nordic region for 15 years. The study found, among other things, that surgery reduces the risk that men with prostate cancer...

TOPICS:

Elsevier, Redfox Technologies and Microsoft launch innovative e-learning nursing solution

May 5, 2011 2:37 pm | by EurekAlert | Comments

(Elsevier) Elsevier, Redfox Technologies and Microsoft today announced the launch of the iCitizen Nursing Skills Netbook, an integrated and affordable e-learning netbook for nurses and nursing students in The Philippines.

TOPICS:

American Regent Initiates Nationwide Voluntary Recall of Caffeine & Sodium Benzoate Injection, USP 250 mg/mL, 2 mL Single Dose Vial Due to Visible Particulates

May 5, 2011 2:32 pm | by Bio-Medicine.Org | Comments

SHIRLEY, N.Y., May 5, 2011 /- American Regent is conducting a nationwide voluntary recall to the consumer and user level of the following product: Caffeine & Sodium Benzoate Injection, USP, 250 mg/mL, 2 mL Single Dose Vial, NDC # 0517-2502-10, Lot # 0084,  Exp Date...

TOPICS:

Power Wheelchairs Keep Medicare Beneficiaries Out of Nursing Homes, While Reducing Government Costs and Providing More Freedom and Independence

May 5, 2011 2:32 pm | by Bio-Medicine.Org | Comments

OCEANSIDE, Calif., May 5, 2011 /PRNewswire-USNewswire/ -- For Judith Talnadge, a power wheelchair provided through Medicare is the difference between living independently in her apartment, with opportunities to visit with friends and engage in the community, or being confined to a nursing...

TOPICS:

Advanced BioHealing plans $200M IPO

May 5, 2011 12:38 pm | by Mass High Tech: The Journal of New England Technology | Comments

Advanced BioHealing Inc., a Westport, Conn.-based developer of cell-based regenerative skin therapy, has filed terms of an initial public offering, for which it plans to raise about $200 million.

Advertisement

Xlumena Receives CE Mark for Revolutionary AXIOSâ„¢ Stent and Delivery System

May 5, 2011 11:36 am | by Bio-Medicine.Org | Comments

MOUNTAIN VIEW, Calif., May 5, 2011 /- Xlumena, Inc., a privately-held provider of innovative technology for the interventional endoscopist and endoscopic surgeon, announced today that it has received CE Mark approval for its revolutionary AXIOS™ Stent and Delivery System (AXIOS)....

TOPICS:

SCAI Releases Position Statement on Public Reporting and Risk Adjustment In Cardiovascular Quality Improvement Programs

May 5, 2011 11:34 am | by Bio-Medicine.Org | Comments

BALTIMORE, May 5, 2011 /- A new position statement released today by the Society for Cardiovascular Angiography and Interventions (SCAI) calls for changes in the way quality of percutaneous coronary intervention (PCI, also known as angioplasty) care is measured and publically reported....

TOPICS:

SCAI Announces National Quality Program to Improve Cardiovascular Patient Care

May 5, 2011 11:33 am | by Bio-Medicine.Org | Comments

BALTIMORE, May 5, 2011 /- Today at the Society for Cardiovascular Angiography and Interventions (SCAI) 2011 Scientific Sessions, SCAI announced its national quality improvement program to measure and improve quality in the cath lab for better patient care. Building on its legacy of using...

TOPICS:

Providing More Detailed Diagnosis in Less Time

May 5, 2011 11:32 am | by Bio-Medicine.Org | Comments

SHENZHEN, China, May 5, 2011 /PRNewswire-Asia/ -- People have become more and more intent on enjoying convenience at communal facilities and getting more services in food, clothing, housing, and transport. However, it is still very difficult for sick people to get timely and easy...

TOPICS:

Kendle to sell company for $232M to INC Research

May 5, 2011 10:45 am | by The Associated Press | Comments

Contract research organization INC Research LLC will buy rival Kendle International Inc. for $232 million in cash, the companies said on Thursday, creating a larger company focusing on drug development services.INC, which is based in Raleigh, N.C. and privately held by Avista Capital Partners...

Innovatient connects with $1M funding round

May 5, 2011 10:38 am | by Mass High Tech: The Journal of New England Technology | Comments

Innovatient Solutions Inc., a health information startup in Farmington, Conn., has raised $1 million in a funding round led by a $500,000 financing from Connecticut Innovations.

Spring Bank Pharma wins $3.9M NIH grant to fight Hep B

May 5, 2011 10:37 am | by Mass High Tech: The Journal of New England Technology | Comments

Milford company Spring Bank Pharmaceuticals Inc. has landed a $3.9 million grant from the National Institutes of Health to further develop a drug candidate to treat Hepatitis B infections.

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading